Literatur
- 1
Arici M, Erdem Y.
Dual blockade of the renin-angiotensin
system for cardiorenal protection: an update.
Am J Kidney
Dis.
2009;
53
332-345
- 2
Bopp A, Herbst V.
Handbuch Medikamente: Vom
Arzt verordnet – für Sie bewertet.
Stiftung Warentest.
2008;
717
- 3
Campbell D J.
Renin-angiotensin system inhibition: how much is too much of
a good thing?.
Intern Med J.
2002;
32
616-620
- 4
Chaudhary K, Nistala R, Whaley-Connell A.
Dual renin-angiotensin system blockade in the ONTARGET study:
clinically relevant risk for the kidney?.
Curr Hypertens
Rep.
2009;
11
375-381
- 5 Hochdruckliga .Leitlinien
zur Behandlung der arteriellen Hypertonie. 2008
- 6
Kunz R, Friedrich C, Wolbers M. et al .
Meta-analysis: effect of monotherapy and
combination therapy with inhibitors of the renin angiotensin system
on proteinuria in renal disease.
Ann Intern Med.
2008;
148
30-48
- 7
Mancia G, De Backer G, Dominiczak A. et al .
2007 Guidelines for the management of arterial
hypertension: The Task Force for the Management of Arterial Hypertension
of the European Society of Hypertension (ESH) and of the European
Society of Cardiology (ESC).
Eur Heart J.
2007;
28
1462-1536
- 8
Nakao N, Yoshimura A, Morita H. et al .
Combination treatment of angiotensin-II
receptor blocker and angiotensin-converting-enzyme inhibitor in
non-diabetic renal disease (COOPERATE): a randomised controlled
trial.
Lancet.
2003;
361
117-124
- 9
Rahn K H.
Leitliniengerechte Differenzialtherapie der Hypertonie.
Internist.
2009;
50
433-441
- 10
Yusuf S, Teo K K, Pogue J. et al .
Telmisartan, ramipril, or both in patients
at high risk for vascular events.
N Engl J Med.
2008;
358
1547-1559
C. Schindler
M. Kosa
J. Schröder
W. Kirch
Institut
für Klinische Pharmakologie, Medizinische Fakultät,
TU Dresden
Fiedlerstraße 27
01307 Dresden
Telefon: 0351/458-2027
Fax: 0351/458-8918
eMail: christoph.schindler@tu-dresden.de
